Zosia Chustecka // DISCLOSURES March 23, 2018 .
A new option for the treatment of ovarian cancer could soon be available in Europe: the PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitor rucaparib (Rubraca, Clovis).
At its latest meeting the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) recommended a conditional marketing authorization for rucaparib for the treatment of relapsed or progressive ovarian cancer with a BRCA mutation.
...